Literature DB >> 1133681

Bioavailability and pharmacokinetics of prednisone in humans.

A R Disanto, K A Desante.   

Abstract

In a clinical study involving 22 normal adult volunteers, the bioavailability and pharmacokinetics of prednisone tablets with varying dissolution rates were evaluated. Serum levels were measured by a radioimmunoassay for prednisolone. Absorption rate constants and serum half-lives are presented. Substantial serum levels of prednisolone were attained quite rapidly (within 0.5 hr). The observed serum levels were statistically analyzed and fitted to the one-compartment open model with first-order absorption and elimination. A qualitative correlation between the in vitro dissolution rate and the calculated initial absorption rate constants was found. However, the in vitro dissolution rates were not predictive of the overall bioavailability of the prednisone tablets tested in terms of peak concentration and area under the serum concentration-time curve.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1133681     DOI: 10.1002/jps.2600640122

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  A radioimmunoassay method for prednisolone: comparison with the competitive protein binding method.

Authors:  J Chakraborty; J English; V Marks; M C Dumasia; D J Chapman
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

2.  Comparative bioavailability: eight commercial prednisone tablets.

Authors:  T J Sullivan; M R Hallmark; E Sakmar; D J Weidler; R H Earhart; J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

Review 3.  Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.

Authors:  J G Gambertoglio; W J Amend; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

4.  Dose dependent pharmacokinetics of prednisolone.

Authors:  M E Pickup; J R Lowe; P A Leatham; V M Rhind; V Wright; W W Downie
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

5.  Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema.

Authors:  D A Lee; G M Taylor; V H James; G Walker
Journal:  Gut       Date:  1979-05       Impact factor: 23.059

6.  Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis.

Authors:  N H Bell; P H Stern; E Pantzer; T K Sinha; H F DeLuca
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

7.  Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.

Authors:  M Davis; R Williams; J Chakraborty; J English; V Marks; G Ideo; S Tempini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

8.  Randomized clinical trial comparing oral prednisone (50 mg) with placebo before laparoscopic cholecystectomy.

Authors:  Thue Bisgaard; Svend Schulze; Niels Christian Hjortsø; Jacob Rosenberg; Viggo Bjerregaard Kristiansen
Journal:  Surg Endosc       Date:  2007-12-20       Impact factor: 4.584

9.  Plasma prednisolone measurements in renal transplant patients.

Authors:  J Chakraborty
Journal:  Ulster Med J       Date:  1981

10.  Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.

Authors:  Miguel Debono; Ashwini Mallappa; Verena Gounden; Aikaterini A Nella; Robert F Harrison; Christopher A Crutchfield; Peter S Backlund; Steven J Soldin; Richard J Ross; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2015-09-04       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.